(NBC News) The Food and Drug Administration has approved the first medication in a new class of drugs to control high cholesterol.
In clinical trials a new class of injectable drugs called “PCSK9 inhibitors” lowered levels of bad cholesterol by about 60-percent.
“It’s not the answer for everyone, but it may be a component of treatment for a large segment of the population that still has a risk of heart disease even on statins or that can’t take statin drugs,” says Dr. Barry Effron of UH Case Medical Center.
It’s unknown whether the drugs will lead to fewer heart attacks and strokes.
That lack of data could be problematic for insurance companies faced with paying for these newer drugs that some estimate could cost as much as $12,000 dollars a year, but they could be the best shot for patients like Arnstine to control their bad cholesterol for good.